---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-023401"
form_type: "8-K"
ticker: "AMGN"
cik: "0000318154"
company_name: "AMGEN INC"
filed_at: "2022-01-31T23:59:59+00:00"
generated_at: "2026-06-27T13:46:49.782678+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Amgen amends Aimovig collaboration with Novartis, ends US royalties and cost-sharing

## Summary
- Novartis gets sole commercialization rights for Aimovig outside US and Japan; Amgen ends royalty payments on US sales.
- U.S. Collaboration Agreement terminated Jan 31, 2022; parties no longer share US commercialization costs.
- Amgen's share of Franchise Product 1 (Aimovig) development costs capped at $[***] aggregate; thereafter split 50/50.
- Litigation between the parties resolved concurrently with these amendments.
- Novartis to fund US Medical Affairs activities until a defined completion date.

## SEC filing metadata
- accession: 0001193125-22-023401
- form_type: 8-K
- ticker: AMGN
- cik: 0000318154
- company_name: AMGEN INC
- filed_at: 2022-01-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318154/000119312522023401/0001193125-22-023401-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318154/000119312522023401/d275986d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-023401
- JSON: https://secwatch.observer/filing/0001193125-22-023401.json
- Plain text: https://secwatch.observer/filing/0001193125-22-023401.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.